Sulopenem (CP-70429) is an orally active gastrointestinal-external cephalosporin antibiotic with broad-spectrum antibacterial activity. It inhibits Gram-positive and Gram-negative bacteria and can be used in bacterial infection research.

E. coli:0.015-0.12 µg/mL (MIC)

Sulopenem exhibits potential for the treatment of simple and complicated urinary tract infections and intra-abdominal infections, especially for multi-drug resistant (MDR) infections and infections caused by quinolone-ineffective and/or broad-spectrum beta-lactamase-producing (ESBL) gram-negative bacilli. [1]
Sulopenem inhibits the growth of most aerobic and anaerobic Gram-positive and Gram-negative bacteria, including methicillin-sensitive Staphylococcus aureus, Streptococcus pneumoniae (including penicillin-sensitive and resistant strains), group A and B beta-hemolytic streptococci, Listeria monocytogenes, Enterobacteriaceae, Haemophilus influenzae, and Catamorpha but is ineffective against Pseudomonas aeruginosa and Stenotrophomonas maltophilia. Aeromonas, and its inhibitory activity is evident at concentrations ≤1 μg/mL. [1]

In a mouse model of experimental systemic infection, Sulopenem was superior to imipenem/cilastatin in terms of protective capacity. Sulopenem showed lower ED50 values in mice mixed infection with Escherichia coli and Mimosella fragilis. In addition, Sulopenem was superior to CZON or cefotiam in a guinea pig model of experimental lung infection (caused by Klebsiella pneumoniae). [2]